A Study Comparing Efficacy And Safety Of Dabigatran And Rivaroxaban Versus Warfarin In Patients With Persistent And Long-Standing Atrial Fibrillation Undergoing Electrical Cardioversion With High Risk Of Stroke And Embolism
Latest Information Update: 05 Jan 2017
Price :
$35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2017 New trial record
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association.